- Home
- ACIU vs IMMP Comparison
ACIU vs IMMP Comparison
Compare ACIU & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- IMMP
- Stock Information
- Founded
- ACIU 2003
- IMMP 1987
- Country
- ACIU Switzerland
- IMMP Australia
- Employees
- ACIU N/A
- IMMP N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- ACIU Health Care
- IMMP Health Care
- Exchange
- ACIU Nasdaq
- IMMP Nasdaq
- Market Cap
- ACIU 332.4M
- IMMP 304.0M
- IPO Year
- ACIU 2016
- IMMP N/A
- Fundamental
- Price
- ACIU $2.68
- IMMP $2.03
- Analyst Decision
- ACIU Strong Buy
- IMMP Buy
- Analyst Count
- ACIU 2
- IMMP 2
- Target Price
- ACIU $12.00
- IMMP $8.50
- AVG Volume (30 Days)
- ACIU 134.5K
- IMMP 159.0K
- Earning Date
- ACIU 11-05-2024
- IMMP 01-03-2025
- Dividend Yield
- ACIU N/A
- IMMP N/A
- EPS Growth
- ACIU N/A
- IMMP N/A
- EPS
- ACIU N/A
- IMMP N/A
- Revenue
- ACIU $48,505,404.00
- IMMP $2,563,302.00
- Revenue This Year
- ACIU $85.33
- IMMP N/A
- Revenue Next Year
- ACIU $80.69
- IMMP $10.84
- P/E Ratio
- ACIU N/A
- IMMP N/A
- Revenue Growth
- ACIU 4097200.00
- IMMP 9.59
- 52 Week Low
- ACIU $2.25
- IMMP $1.66
- 52 Week High
- ACIU $5.14
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- ACIU 27.49
- IMMP 47.96
- Support Level
- ACIU $2.62
- IMMP $2.00
- Resistance Level
- ACIU $3.02
- IMMP $2.24
- Average True Range (ATR)
- ACIU 0.13
- IMMP 0.13
- MACD
- ACIU -0.05
- IMMP -0.01
- Stochastic Oscillator
- ACIU 9.52
- IMMP 25.00
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.